Evidence for partial pharmaceutical reversal of the cancer anorexia–cachexia syndrome: The case of anamorelin

Journal of Cachexia, Sarcopenia and Muscle

Volumn 6, Issue 4, 2015, Pages 275-277

  Anker, Stefan D ^a   Coats, Andrew J S ^b,c   Morley, John E ^d  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF WARWICK   (United Kingdom)

^d SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAMORELIN;

ANOREXIA; CACHEXIA; EDITORIAL; FOOD INTAKE; FUNCTIONAL ASSESSMENT; GRIP STRENGTH; HUMAN; LEAN BODY WEIGHT; MUSCLE ATROPHY; MUSCLE FUNCTION; MUSCLE MASS; MUSCLE STRENGTH; PRIORITY JOURNAL; QUALITY OF LIFE; WALKING SPEED; WEIGHT REDUCTION;

EID: 84951559515     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1002/jcsm.12063     Document Type: Editorial

References (28)

1. Argiles JM, Anker SD, Evans WJ, Morley JE, Fearon KC, Strasser F, et al. Consensus on cachexia definitions. J Am Med Dir Assoc 2010; 11: 229–230.
2. Bauer J, Biolo G, Cederholm T, Cesari M, Cruz-Jentoft AJ, Morley JE, et al. Evidencebased recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE study group. J Am Med Dir Assoc 2013; 14: 542–559.
3. Omlin A, Blum D, Wierecky J, Haile SR, Ottery FD, Strasser F. Nutrition impact symptoms in advanced cancer patients: frequency and specific interventions, a case–control study. J Cachexia Sarcopenia Muscle 2013; 4: 55–61.
4. Morley JE, von Haehling S, Anker SD. Are we closer to having drugs to treat muscle wasting disease? J Cachexia Sarcopenia Muscle 2014; 5: 83–87.
5. von Haehling S, Anker SD. Treatment of cachexia: an overview of recent developments. J Am Med Dir Assoc 2014; 15: 866–872.
6. Morley JE. Pathophysiology of the anorexia of aging. Curr Opin Clin Nutr Metab Care 2013; 16: 27–32.
7. Dobs AS, Boccia RV, Croot CC, Gabrail NY, Dalton JT, Hancock ML, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a doubleblind, randomized controlled phase 2 trial. Lancet Oncol 2013; 14: 335–345.
8. Müller TD, Nogueiras R, Andermann ML, Andrews ZB, Anker SD, Argente J, et al. Ghrelin. Mol Metab 2015; 4: 437–460.
9. Diano S, Farr SA, Benoit SC, McNay EC, da Silva I, Horvath B, et al. Ghrelin controls hippocampal spine synapse density and memory performance. Nat Neurosci 2006; 9: 382–388.
10. Gaskin FS, Farr SA, Banks WA, Kumar VB, Morley JE. Grhelin-induced feeding is dependent on nitric oxide. Peptides 2003; 24: 913–918.
11. Garcia JM, Boccia RV, Graham CD, Yan Y, Duus EM, Allen S, et al. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomized, placebocontrolled, double-blind trials. Lancet Oncol 2015; 16: 108–116.
12. Morley JE. Scientific overview of hormone treatment used for rejuvenation. Fertil Steril 2013; 99: 1807–1813.
13. Barbat-Artigas S, Rolland Y, Vellas B, Aubertin-Leheudre M. Muscle quantity is not synonymous with muscle quality. J Am Med Dir Assoc 2013; 14: 852.e1–852.e7.
14. Woo J, Leung J, Morley JE. Validating the SARC-F: a suitable community screening tool for sarcopenia? J Am Med Dir Assoc 2014; 15: 630–634.
15. Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS, et al. Sarcopenia in Asia: consensus report of the Asian working group for sarcopenia. J Am Med Dir Assoc 2014; 15: 95–101.
16. Veasey Rodrigues H, Baracos VE, Wheler JJ, Parsons HA, Hong DS, Naing A, et al. Body composition and survival in the early clinical trials setting. Eur J Cancer 2013; 49: 3068–3075.
17. Kalantar-Zadeh K, Rhee C, Sim JJ, Stenvinkel P, Anker SD, Kovesdy CP. Why cachexia kills: examining the causality of poor outcomes in wasting conditions. J Cachexia Sarcopenia Muscle 2013; 4: 89–94.
18. Cousin S, Hollebecque A, Koscielny S, Mir O, Varga A, Baracos VE, et al. Low skeletalmuscle is associated with toxicity in patients included in phase I trials. Invest New Drugs 2014; 32: 382–387.
19. Anker SD, Coats AJ, Morley JE, Rosano G, Bernabei R, von Haehling S, et al. Muscle wasting disease: a proposal for a new disease classification. J Cachexia Sarcopenia Muscle 2014; 5: 1–3.
20. Toledo M, Springer J, Busquets S, Tschirner A, López-Soriano FJ, Anker SD, et al. Formoterol in the treatment of experimental cancer cachexia: effects on heart function. J Cachexia Sarcopenia Muscle 2014; 5: 315–320.
21. Fogelman DR, Holmes H, Mohammed K, Katz MH, Prado CM, Lieffers J, et al. Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer? J Cachexia Sarcopenia Muscle 2014; 5: 307–313.
22. de Campos-Ferraz PL, Andrade I, das Neves W, Hangai I, Alves CR, Lancha AH Jr. An overview of amines as nutritional supplements to counteract cancer cachexia. J Cachexia Sarcopenia Muscle 2014; 5: 105–110.
23. Rattanasompattikul M, Molnar MZ, Lee ML, Dukkipati R, Bross R, Jing J, et al. Anti-Inflammatory and Anti-Oxidative Nutrition in Hypoalbuminemic Dialysis Patients (AIONID) study: results of the pilot-feasibility, double-blind, randomized, placebo-controlled trial. J Cachexia Sarcopenia Muscle 2013; 4: 247–257.
24. Khawaja T, Chokshi A, Ji R, Kato TS, Xu K, Zizola C, et al. Ventricular assist device implantation improves skeletal muscle function, oxidative capacity, and growth hormone/insulin-like growth factor-1 axis signaling in patients with advanced heart failure. J Cachexia Sarcopenia Muscle 2014; 5: 297–305.
25. Knops M, Werner CG, Scherbakov N, Fiebach J, Dreier JP, Meisel A, et al. Investigation of changes in body composition, metabolic profile and skeletal muscle functional capacity in ischemic stroke patients: the rationale and design of the Body Size in Stroke Study (BoSSS). J Cachexia Sarcopenia Muscle 2013; 4: 199–207.
26. Scott IC, Tomlinson W, Walding A, Isherwood B, Dougall IG. Large-scale isolation of human skeletal muscle satellite cells from post-mortem tissue and development of quantitative assays to evaluate modulators of myogenesis. J Cachexia Sarcopenia Muscle 2013; 4: 157–169.
27. Pötsch MS, Tschirner A, Palus S, von Haehling S, Doehner W, Beadle J, et al. The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats. J Cachexia Sarcopenia Muscle 2014; 5: 149–158.
28. Morley JE, von Haehling S, Anker SD, Vellas B. From sarcopenia to frailty: a road less traveled. J Cachexia Sarcopenia Muscle 2014; 5: 5–8.